Jinwan stands out at biomed conference in Shizimen

The ChinaBio Partnering Forum 2017 opened at the Zhuhai International Convention & Exhibition Center in Shizimen Central Business District on May 31.

Eight hundred industry insiders and representatives from over 300 pharmaceutical enterprises and renowned investment and consulting organizations from more than 30 countries and territories attended. They discussed development and cooperation prospects of the medical industry in Jinwan District, Zhuhai and the whole country during the forum.

Also known as the 9th Annual International Partnering Conference, ChinaBio is the premier life-science networking event in China. Sponsored by the Zhuhai Bureau of Commerce, Jinwan District government and Ruike Enterprise Management (Shanghai), the forum provides a means to present company innovations and science-driven technologies to potential business partners.

ChinaBio Partnering Forum 2017   

Launched by the US EBD Group, the leading partnering firm in the life-science industry, ChinaBio has been held eight times. It has attracted biotech and pharma leaders including Pfizer, Roche, and Merck along with hundreds of China-based developers of novel technologies.

Jinwan District, a cluster for the biomedicine industry, has attracted over 100 well-known enterprises such as United Laboratories and Livzon. A complete industry chain includes research, development, production, and logistics of biopharmaceutical, TCM preparations, chemical drugs, medical apparatus and instruments, and healthcare products.

In 2016, the gross output value of Jinwan's biomedicine industry reached 20 billion yuan ($2.9 billion), about two-thirds of the city's total in the industry. Known as Guangdong's Top 3 largest biomedicine industrial bases, Jinwan has been cited as a National New Industrialization Base by the Ministry of Industry & Information Technology of China.

ChinaBio Partnering Forum 2017 [Photos by Wang Yue]

To accelerate the development of the biomedicine industry, the district plans to construct the 10-sq-km Jinwan Biomedicine Park. It also invested 1.6 billion yuan ($235 million) to work with established domestic enterprises on the Zhuhai International Health Port project, which is to have floor space of 278,000 sq m.

In addition, Jinwan has commenced construction of five public service agencies -- Food & Drug Authentication, Laboratory Animal, Biomedical Inspection & Detection, Generic Drug Quality Research, and GMP Training & Education centers. They provide enterprises with R&D, detection, pilot tests, production, incubation, financing, and fast administrative examination and approval. The first-phase project is expected to become operational in October.